An observational human laboratory assessment of nicotine delivery, vaping topography and subjective effects of usual brand electronic cigarette use among young adults.

What Was Tested

This observational study looks at Therapeutic nicotine (patch, non-peptide).

To measure nicotine delivery, vaping topography and subjective effects of current generations of disposable, cartridge-based and other types of electronic cigarettes (e-cigarettes) among young adults.

Who Took Part

PubMed indexes the participants as teenagers, young adults and adults, both men and women.

Observational, human laboratory assessment of e-cigarette use in Columbus, Ohio, USA (July 2020 to June 2021).

Participants completed a pre-vaping questionnaire, vaped their usual brand of e-cigarette ad libitum for 30 min and completed a post-vaping questionnaire.

How the Study Was Run

Outcome variables included pre- and post-vaping measures of plasma nicotine (t = 0 and t = 30, respectively) and craving and withdrawal symptoms, as well as vaping topography (e.g. flow rate and inter-puff interval), pre-vaping expectancies and post-vaping product appeal.

Variables used to characterize the sample included demographics, e-cigarette and other tobacco use history, e-cigarette dependence and e-cigarette device characteristics (e.g. device type, flavor and nicotine form).

What Was Measured

Topics PubMed links to this paper include Vaping, Electronic Nicotine Delivery Systems, Nicotine, Substance Withdrawal Syndrome, Craving, Ohio and Surveys and Questionnaires.

Author keywords: abuse liability, electronic cigarettes, nicotine withdrawal, vaping topography and young adults.

What This Means in Plain Language

This is an observational study of Therapeutic nicotine (patch, non-peptide).

The abstract goes on to report its results in about 5 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2025 (Addiction (Abingdon, England)), a journal based in England.

More context: the Therapeutic nicotine (patch, non-peptide) compound page, all human trials.